A Pilot Study of Stored Low Titer Group O Whole Blood + Component Therapy versus Component Therapy Only for Civilian Trauma Patients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Anaar E. Siletz ◽  
Kevin J. Blair ◽  
Richelle J. Cooper ◽  
N. Charity Nguyen ◽  
Scott J. Lewis ◽  
...  
Keyword(s):  
Pilot Study ◽  
Whole Blood ◽  
Blood Component ◽  
Trauma Patients ◽  
Civilian Trauma ◽  
Blood Component Therapy ◽  
Titer Group

Whole Blood Versus Conventional Blood Component Massive Transfusion Protocol Therapy in Civilian Trauma Patients

2021 ◽  
pp. 000313482110497
Author(s):  
Janet S. Lee ◽  
Abid D. Khan ◽  
Franklin L. Wright ◽  
Robert C. McIntyre ◽  
Warren C. Dorlac ◽  
...  
Keyword(s):  
Whole Blood ◽  
Injury Severity ◽  
Massive Transfusion ◽  
Blood Component ◽  
Trauma Patients ◽  
Massive Transfusion Protocol ◽  
Civilian Trauma ◽  
Transfusion Volume ◽  
Blood Component Therapy ◽  
Transfusion Protocol

Background Military data demonstrating an improved survival rate with whole blood (WB) have led to a shift toward the use of WB in civilian trauma. The purpose of this study is to compare a low-titer group O WB (LTOWB) massive transfusion protocol (MTP) to conventional blood component therapy (BCT) MTP in civilian trauma patients. Methods Trauma patients 15 years or older who had MTP activations from February 2019 to December 2020 were included. Patients with a LTOWB MTP activation were compared to BCT MTP patients from a historic cohort. Results 299 patients were identified, 169 received LTOWB and 130 received BCT. There were no differences in age, gender, or injury type. The Injury Severity Score was higher in the BCT group (27 vs 25, P = .006). The LTOWB group had a longer transport time (33 min vs 26 min, P < .001) and a lower arrival temperature (35.8 vs 36.1, P < .001). Other hemodynamic parameters were similar between the groups. The LTOWB group had a lower in-hospital mortality rate compared to the BCT group (19.5% vs 30.0%, P = .035). There were no differences in total transfusion volumes at 4 hours and 24 hours. No differences were seen in transfusion reactions or hospital complications. Multivariable logistic regression identified ISS, age, and 24-hour transfusion volume as predictors of mortality. Discussion Resuscitating severely injured trauma patient with LTOWB is safe and may be associated with an improved survival.

The use of low-titer group O whole blood for the resuscitation of civilian trauma patients in 2018

Transfusion ◽  
2018 ◽  
Vol 58 (11) ◽  
pp. 2744-2746 ◽  
Author(s):  
Mark H. Yazer ◽  
Philip C. Spinella
Keyword(s):  
Whole Blood ◽  
Trauma Patients ◽  
Civilian Trauma ◽  
Titer Group

scholarly journals Hemolytic markers following the transfusion of uncrossmatched, cold‐stored, low‐titer, group O+ whole blood in civilian trauma patients

Transfusion ◽  
2020 ◽  
Vol 60 (S3) ◽  
Author(s):  
Ian M. Harrold ◽  
Jansen N. Seheult ◽  
Louis H. Alarcon ◽  
Alain Corcos ◽  
Jason L. Sperry ◽  
...  
Keyword(s):  
Whole Blood ◽  
Trauma Patients ◽  
Civilian Trauma ◽  
Titer Group

scholarly journals Whole Blood, Fixed Ratio, or Goal-Directed Blood Component Therapy for the Initial Resuscitation of Severely Hemorrhaging Trauma Patients: A Narrative Review

2021 ◽  
Vol 10 (2) ◽  
pp. 320
Author(s):  
Mark Walsh ◽  
Ernest E. Moore ◽  
Hunter B. Moore ◽  
Scott Thomas ◽  
Hau C. Kwaan ◽  
...  
Keyword(s):  
Whole Blood ◽  
Fixed Ratio ◽  
Narrative Review ◽  
Blood Component ◽  
Trauma Patients ◽  
Initial Resuscitation ◽  
Blood Component Therapy ◽  
Historical Developments ◽  
Comparative Trials ◽  
Selection Of

This narrative review explores the pathophysiology, geographic variation, and historical developments underlying the selection of fixed ratio versus whole blood resuscitation for hemorrhaging trauma patients. We also detail a physiologically driven and goal-directed alternative to fixed ratio and whole blood, whereby viscoelastic testing guides the administration of blood components and factor concentrates to the severely bleeding trauma patient. The major studies of each resuscitation method are highlighted, and upcoming comparative trials are detailed.

Safety profile of uncrossmatched, cold-stored, low-titer, group O+ whole blood in civilian trauma patients

Transfusion ◽  
2018 ◽  
Vol 58 (10) ◽  
pp. 2280-2288 ◽  
Author(s):  
Jansen N. Seheult ◽  
Marshall Bahr ◽  
Vincent Anto ◽  
Louis H. Alarcon ◽  
Alain Corcos ◽  
...  
Keyword(s):  
Safety Profile ◽  
Whole Blood ◽  
Trauma Patients ◽  
Civilian Trauma ◽  
Titer Group

scholarly journals Blood Component Therapy

2018 ◽  
Vol 9 (2) ◽  
pp. 142-147
Author(s):  
Shanaz Karim ◽  
Ehteshamul Hoque ◽  
Md Mazharul Hoque ◽  
Syeda Masooma Rahman ◽  
Kashfia Islam
Keyword(s):  
Red Blood Cells ◽  
Whole Blood ◽  
Blood Cells ◽  
Fresh Frozen Plasma ◽  
Blood Component ◽  
Packed Red Blood Cells ◽  
Medical College ◽  
Blood Component Therapy ◽  
Fresh Frozen ◽  
Cellular Components

Transfusion medicine has undergone advancements since its initiation in the early 20th century. One of these was the discovery that blood can be divided into individual components and delivered separately. Today, blood transfusions nearly always consist of the ad-ministration of 1 or more components of blood. Whole blood transfusion is now limited to situations involving massive resuscitation (trauma ) The most familiar cellular components include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC and pooled or aphaeresis platelets. Plasma products such as FFP or cryoprecipitate, ant hemophilic factor (CRYO). The transfusion of red blood cells (RBCs), platelets, fresh-frozen plasma (FFP), and cryoprecipitate has the potential of improving clinical outcomes in perioperative and peripartum settings. These benefits include improved tissue oxygenation and decreased bleeding. However, transfusions are not without risks or costs. With the advent of blood component therapy, each unit of whole blood collected serves the specific needs of several, rather than a single patient.Anwer Khan Modern Medical College Journal Vol. 9, No. 2: Jul 2018, P 142-147

scholarly journals Quality Assessment of Established and Emerging Blood Components for Transfusion

2016 ◽  
Vol 2016 ◽  
pp. 1-28 ◽  
Author(s):  
Jason P. Acker ◽  
Denese C. Marks ◽  
William P. Sheffield
Keyword(s):  
Whole Blood ◽  
Blood Product ◽  
Standard Of Care ◽  
Blood Component ◽  
Industrialized Countries ◽  
Platelet Concentrates ◽  
Donor Blood ◽  
Additional Manufacturing ◽  
Blood Component Therapy ◽  
Nonstandard Conditions

Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.

Sign in / Sign up

Export Citation Format

Share Document